Navigation Links
7 Health Ventures Invests in Tulip Medical
Date:9/15/2008

HERZELIA, Israel, September 15 /PRNewswire/ -- 7 Health Ventures, a professional venture capital fund dedicated to investing in healthcare technologies and products, announced today it had joined a deferred closing of Tulip Medical's round A of financing. Dr. Dalia Megiddo, founder and managing partner at 7 Health Ventures, will join Tulip's board of directors.

Tulip Medical Ltd. is a medical device company that is developing the next generation solution for the worldwide overweight and obesity epidemic, focusing on the overweight and mild obese markets.

"The company's products address one of the biggest and most urgent problems the world is facing, which is often referred to as the epidemic of the 21st century" said Dr. Megiddo. "To date, all existing treatments fall short of providing a solution for the ever growing population of the overweight and obese. These solutions are either very aggressive, such as surgery, or very limited in their clinical benefits. Tulip's device has the potential of providing a very effective solution while being extremely safe and easy to use."

Tulip's flagship product is a unique orally taken biodegradable solution wherein patients will experience a long term feeling of satiety free of the severe complications associated with existing solutions. The company has developed a disposable medical device that is swallowed as a regular capsule. The device's mechanism of action is purely mechanical and does not involve any chemical activity.

Tulip was incorporated in Israel in August 2005 by Dr. Shimon Eckhouse, Active Chairman of the company and Doron Marco which serves as the company's CTO. The Company operates from its offices in Herzelia, Israel, and is managed by CEO Allon Reiter.

About 7 Health Ventures

7 Health Ventures is a professional venture capital fund which invests in technology companies developing medical technologies, products and services. The fund which launched its activity
'/>"/>

SOURCE 7 Health Ventures
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Tone Deafness Explained, from the Harvard Health Letter
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
8. ViroPharma to Present at Three Upcoming Healthcare Conferences
9. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
10. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)... -- Biotech scientists increasingly are applying g...ter understand the effects of novel drug candidate...Engineering & Biotechnology News ( GEN ). The...compound,s mechanism of action and eventually deve...g to the November 15 issue of GEN . ( http://www....
(Date:11/18/2008)...l/ -- NeuroDiscovery Ltd (ASX:,NDL), a specialty ... Company,and Sosei Group Corporation ("Sosei"; T...biopharmaceutical company, today announce that Neu...nical efficacy data for NSL-043/SD118.,This inves...thic pain and has,successfully completed Phase I ...
(Date:11/18/2008)...wswire/ -- Forty-two leading U. S. scientists and ...to consider cutting-edge innovations that may defe...om outbreaks of dangerous zoonotic diseases, the F... innovations: , , , , A "Doc in...ts highly contagious and dangerous zoonotic diseas...
(Date:11/13/2008)...FirstCall/ -- Hologic, Inc.,(Nasdaq: HOLX ), a le...ium,diagnostics, medical imaging systems and surgi...eeds of women, today announced the results of the,... Cervista HPV high-risk,test is currently under re...launched in the European Union (EU) early in 2009....
Breaking Medicine Technology:GEN Reports on the Trend Toward Predictive Toxicogenomics 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4322 1Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4322 2Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4322 3Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4322 4Committee to Reduce Infection Deaths Releases 10 Lifesaving Steps to Protect Students from MRSA Infections 4317 1Committee to Reduce Infection Deaths Releases 10 Lifesaving Steps to Protect Students from MRSA Infections 4317 2Abbott Announces Positive One Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 599 1Abbott Announces Positive One Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 599 2Abbott Announces Positive One Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 599 3drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 1drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 2drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 3drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 4drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 5drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 6drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 7drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 8drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 9drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 10drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 11drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 12drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 13drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 14
...NEW YORK--(BUSINESS WIRE)--Apr 12, 2007 - INNOVIVE...d that data from preclinical,studies of INNO-406, ...r for Gleevec-resistant or treatment-intolerant ch...he American Association,for Cancer Research Annual...7 at the Los Angeles Convention Center in Los Ange...
... BRANFORD, Conn., April 12, 2007 /PRNewswire-First...new preclinical data on,belinostat (PXD101), a his...ed for the treatment of cancer, and velafermin, a ...evere oral mucositis,will be presented at the upc...CR) 2007 Annual Meeting in Los Angeles, CA, April,...
Other Medicine Technology:Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4
(Date:11/21/2008)...for preterm labor , , FRIDAY, Nov. 21 (H...e switch that activates the uterine muscles for co...ad to therapies for preterm labor. , The molec...the surface of these uterine muscle cells, keeping...But researchers from Dartmouth Medical School in N...
(Date:11/21/2008)... State University College of Medicine research tea... new layer of regulation in the cell division cycl...the way cancer begins. , Wang, an assistant prof...icine, said the findings will lead to an improved ...esign of new drugs that kill cancer cells by inhib...
(Date:11/21/2008)...re-FirstCall/ -- Heska Corporation,(Nasdaq: HSK...k Society of,Security Analysts, 12th Annual Biote... 2008 at 1177 Avenue of the Americas, 2nd Floor in...egin at 9:35 a.m. Eastern Time (7:35 a.m.,Mountai... for two weeks,following the presentation through...
(Date:11/21/2008)...out future antibiotic resistance from widespread u...) -- People with moderate to severe chronic obstru...ce the frequency of exacerbations through a regula...ays. , The study, published in the first issue...ory and Critical Care Medicine , found that twice-...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2
...ed from patients who are in for these tests. Resea...t present which will help spare some couples the c...e Werlin, M.D., and researchers from the Genesis N...olved in a study looking at the benefits of preimp...
... into energy-producing muscle fibres – mocking the...ard Medical School discovered a protein in muscle ...rsity of Texas, they reveal that the protein has t...There are two types of muscle fibre. Type II is th...
...ry did not improve, attention or concentration in ...l extract much prized for many years for its effec...gested it may be helpful in improving memory //in ...ko can increase mental sharpness in those who are ...
...ioxidant treatment improves circulation and reduce... Peripheral artery disease is a narrowing of the a...cts an estimated 5 million to 10 million people in...have no symptoms, one of the major signs of the co...
Other Medicine News:
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution.
For the quantitative determination of total glucose in serum.
Glucose reagent is used for the quantitative determination of glucose in human serum.
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L). Single vial, dry powder reagent.
Medicine Products: